NCT05403723 2026-02-19
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Phase 1 Suspended
University of Maryland, Baltimore
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
UMC Utrecht
Universitätsmedizin Mannheim